Haematopoietic stem cell treatment
AssigneeThe University Court of the University of Edinburgh
InventorsKamil Romuald Kranc, Dónal O'Carroll
Life of this patent
Estimating the term…
Abstract
The present invention relates to modified haematopoietic stem cells, methods for preparing them, and their use in therapy; as well as methods and reagents for expanding haematopoietic stem cells (HSC) and methods for treating haematological disorders. A particular aspect relates to a method for treating a disease or condition characterised by elevated YTHDF2 expression comprising administering to a patient an effective amount of an YTHDF2 inhibitor. Certain aspects of the invention rely on YTFIDF2 protein level or function and use of YTFIDF2 inhibitors.
Claims7
A method for treating a hematological cancer in a patient in need thereof, comprising administering to the patient an effective amount of an YTHDF2 (YTH domain family 2) inhibitor, wherein the YTHDF2 inhibitor is a nucleic acid based inhibitor molecule selected from the group consisting of a small interfering RNA interference molecule (RNAi), an antisense oligonucleotide (ASO), and a nucleic acid aptamer.
Dependencies are inferred from the claim text.